Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity

Neurology

Volumn 42, Issue 7, 1992, Pages 1367-1370

  Berger, Alan R ^a   Schaumburg, H H ^a   Schroeder, C ^a   Apfel, S ^a   Reynolds, R ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIDOXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; ELECTROPHYSIOLOGY; FEMALE; HUMAN; MALE; NERVE CONDUCTION; NERVE LESION; NERVE REGENERATION; NEUROPATHY; NEUROTOXICITY; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; SELF MEDICATION; SENSORY DYSFUNCTION; SPASTICITY; STRUCTURE ACTIVITY RELATION; SURAL NERVE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; MALE; MIDDLE AGE; NERVOUS SYSTEM DISEASES; NEURAL CONDUCTION; PROSPECTIVE STUDIES; PYRIDOXINE; SENSORY THRESHOLDS; SURAL NERVE;

EID: 0026639426     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.42.7.1367     Document Type: Article

References (20)

1. Cavanagh JB. The significance of the “dying-back” process in experimental and human neurological disease. Int Rev Exp Pathol 1964;3:219-267.
2. Spencer PS, Schaumburg HH, Pathobiology of neurotoxic axonal degeneration. In: Waxman S, ed. Physiology and pathology of axons. New York: Raven Press, 1978.
3. Ross EM, Gilman AG. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman A, Goodman L, Rail T, Marad F, eds. The pharmacological basis of therapeutics. New York: Macmillan, 1985.
4. Schaumburg HH, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983;309:445-448.
5. Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 1989;39:1077-1083.
6. Krinke G, Schaumburg HH, Spencer PS, et al. Pyridoxine megavitaminosis produces degeneration of peripheral sensory neurons (sensory neuronopathy) in the dog. Neurotoxicology 1980;2:13-24.
7. Windebank AJ, Low PA, Blexrud MD, Schmelzer JD, Schaumburg HH. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology 1985;35:1617-1622.
8. Albin RL, Albers JW, Greenberg HS, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987;37:1729-1732.
9. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology 1985;35:1466-1468.
10. Arezzo J, Schaumburg HH. Screening for neurotoxic disease in humans. J Am Coll Toxicol 1989;8:147-155.
11. Arezzo JC, Schaumburg HH. The use of the Optacon as a screening device. J Oceup Med 1980;22:461-464.
12. Arezzo JC, Schaumburg HH, Laudadio C. Thermal sensitivity tester: device for quantitative assessment of diabetic neuropathy. Diabetes 1986;35:590-592.
13. Spencer PS, Schaumburg HH. Central peripheral distal axonopathy: the pathology of dying-back polyneuropathies. In: Zimmerman H, ed. Progress in neuropathology. New York: Grune & Stratton, 1977.
14. Auld RB, Bedwell SF. Peripheral neuropathy with sympathetic overactivity from industrial contact with acrylamide. Can Med Assoc J 1967;96:652-654.
15. Garland TO, Patterson MWH. Six cases of acrylamide poisoning. Br J Ind Med 1967;4:134-138.
16. Post EJ, Mc Leod JG. Acrylamide autonomic neuropathy in the cat. I. Neurophysiological and histological studies. J Neurol Sci 1977;33:353-374.
17. Post EJ, Mc Leod JG. Acrylamide autonomic neuropathy in the cat. II. Effects of mesenteric vascular control. J Neurol Sci 1977;33:375-385.
18. Lowndes HE, Baker T, Eun-Sook C, Jortner BS. Position sensitivity of deafferented muscle spindles in experimental acrylamide neuropathy. J Pharmacol Exp Ther 1978;205:40-48.
19. Lowndes HE, Baker T, Michelson LP, et al. Attenuated dynamic responses of primary endings of muscle spindles: a basis for depressed tendon responses in acrylamide neuropathy. Ann Neurol 1978;3:433-437.
20. De Rojas TO, Goldstein BD. Lack of evidence for the size principle of selective vulnerability of axons in toxic neuropathies. I. The effects of subcutaneous injections of 2,5- hexanedione on behavior and muscle spindle function. Toxicol Appl Pharmacol 1990;104:47-58.